Summary
Introduction
Functional imaging of neuroendocrine tumours has become possible as a result of two characteristics of the tumour cells. The first is that they express somatostatin receptors and therefore can be imaged with lndium l11 -labelled octreotide (Octreoscan). 1T he second characteristic of neuroendocrine tumours is that amine precursors are taken up into the cells by a specific amine precursor uptake/decarboxylase (APUD) pathway. Labelling of physiological amine precursors was unsuccessful, but metaiodobenzylguanidine (MIBG) is taken up by the same pathway and is concentrated in tumours cells, and thus I 123 -labelled MIBG can be used for imaging. 5 " 7 Furthermore, tumours which concentrate MIBG on scanning may respond to local radiation therapy with I 131 MIBG. 8 " 10 Imaging is becoming increasingly important in order to document extrahepatic spread in those considered for hepatic surgery 11 transplantation 12 ' 13 or for monitoring responses to chemotherapy. 14 In the present study, octreotide and MIBG scanning were directly compared in 18 patients with neuroendocrine tumours of the liver to determine the relative accuracy and clinical value of the two methods.
Methods
The 18 patients studied had either histologicallyproven neuroendocrine tumours of the liver (by chromogranin staining and histological appearance) or positive urinary 5HIAA (at least three times normal range). Two of the patients (2 and 5) were scanned for the first time after liver transplant which had been performed for severe symptoms unresponsive to medical therapy.
All patients adhered to a standard protocol. Potassium iodate was administered 24 h prior to MIBG to block thyroid uptake. 
Results
In 17 (94%) of the 18 patients, definite lesions within the liver were demonstrable with Octreoscan ( Table 1 ). The one patient (patient 4) in which no liver lesion was identified by Octreoscan had Carney's triad 15 (of gastrointestinal leimyoma, pulmonary chondroma and extra-adrenal apudoma) in which the neuroendocrine tumour of the liver may be atypical. In 5/18 patients, Octreoscan identified a primary site although in all of these this site was previously known (Figure 1 ). In a further two cases with a known primary site this was not demonstrated by the Octreoscan. The known primary sites in these seven patients had previously been picked up by CT scanning of the pancreatic primary sites (four patients), and by small bowel barium studies (two patients) or laparotomy (one patient) in the cases with ileal lesions.
In the two patients (2 and 5) studied posttransplant, widespread bony metastases were seen as a result of tumour recurrence, and these had not been previously diagnosed. Both had liver lesions in addition to bony metastases ( Figure 2) . Ten of the patients were studied with Octreoscan while they were concurrently taking octreotide for relief of symptoms and this appeared not to interfere with uptake of the isotope within tumour.
Using MIBG scanning, only seven (39%) of the 18 cases had positive uptake within the liver lesions. Two of the primary sites were also positive for MIBG (Figure 2 ). In two further cases, photon-deficient areas were clearly seen within the liver, and the same lesions had been photon-dense on Octreoscan. None of the bone lesions in patients 2 and 5 shown on Octreoscan were positive with MIBG. In only two patients (10 and 11) were primary sites seen using MIBG, and no previously occult primary sites were revealed by this method.
Discussion
This study has confirmed the clinical use of Octreoscan scintigrams in defining intrahepatic neuroendocrine tumours shown previously. 3 important prior to liver transplantation, which is now an accepted therapy for these tumours. 12 ' 17 When bone metastases occur, these are easily detected by Octreoscan, and the whole-body imaging facility makes it more useful than other imaging techniques in this respect. Octreoscan is not as sensitive at detecting sites of the primary tumour. Only 5/7 known primary lesions were detected by Octreoscan, and this did not identify any additional primary sites that were occult by other imaging methods. Single photon emission tomography (SPET) scanning was shown to be important for correctly identifying liver metastases and separating these from the appearance of normal renal uptake. Areas within the hepatic tumours that accumulate labelled octreotide but leave photon-deficient areas on MIBG scans are of uncertain significance as yet. Concurrent administration of octreotide prior to scanning may improve visualization of lesions, as previously described. 18 Octreoscan is an important investigation for The therapy has not produced objective reduction in tumour size in significant numbers of patients but may have a role in reducing hormone secretion. 8 "
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Our results show that only a relatively small proportion of patients could be treated in this way.
